Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.22.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Revenue, net $ 41,314 $ 32,398
Cost of revenue (excluding amortization of $4,064 and $4,461, respectively) 23,369 21,673
Gross profit 17,945 10,725
Operating expenses:    
Sales and marketing 10,067 9,254
Research and development 1,882 2,795
General and administrative 13,669 18,192
Transition expense 2,585 2,578
Loss on DiamiR transaction 13
Acquisition related amortization expense 4,064 4,461
Change in fair value of contingent consideration (338) (489)
Total operating expenses 31,942 36,791
Operating loss (13,997) (26,066)
Interest accretion expense (496) (549)
Related party interest (424)
Other (expense) income, net (496) 467
Loss from continuing operations before tax (15,413) (26,148)
(Benefit) provision for income taxes (667) 53
Loss from continuing operations (14,746) (26,201)
Loss from discontinued operations, net of tax (197) (250)
Net loss (14,943) (26,451)
Less adjustment for preferred stock deemed dividend (3,033)
Net loss attributable to common stockholders $ (14,943) $ (29,484)
Basic and diluted loss per share of common stock:    
From continuing operations $ (3.57) $ (7.26)
From discontinued operations (0.04) (0.06)
Net loss per basic and diluted share of common stock $ (3.61) $ (7.32)
Weighted average number of common shares and common share equivalents outstanding:    
Basic 4,135 4,029
Diluted 4,135 4,029